Physiologically based pharmacokinetic model of midazolam disposition during pregnancy

Proceedings of the 30th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, EMBS'08 - "Personalized Healthcare through Technology"

Volumn , Issue , 2008, Pages 5454-5457

  Andrew, Marilee A ^a   Hebert, Mary F ^b   Vicini, Paolo ^a  

^a University of Washington   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETICS; OBSTETRICS; PHARMACOKINETICS; PHYSIOLOGY;

MIDAZOLAM; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS; PLASMA CONCENTRATION; PREGNANT WOMAN; WHOLE BODY;

PHYSIOLOGICAL MODELS;

ANXIOLYTIC AGENT; MIDAZOLAM;

ANTIBODY SPECIFICITY; ARTICLE; BIOLOGICAL MODEL; BLOOD; COMPUTER SIMULATION; FEMALE; FETOMATERNAL TRANSFUSION; FETUS; HUMAN; METABOLIC CLEARANCE RATE; METABOLISM; PHYSIOLOGY; PREGNANCY; TISSUE DISTRIBUTION;

ANTI-ANXIETY AGENTS; COMPUTER SIMULATION; FEMALE; FETUS; HUMANS; MATERNAL-FETAL EXCHANGE; METABOLIC CLEARANCE RATE; MIDAZOLAM; MODELS, BIOLOGICAL; ORGAN SPECIFICITY; PREGNANCY; TISSUE DISTRIBUTION;

EID: 61849148259     PISSN: None     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1109/iembs.2008.4650448     Document Type: Conference Paper

References (14)

1. G. J. Anger and M. Piquette-Miller, "Pharmacokinetic studies in pregnant women," Clin Pharmacol Ther., vol 83, no. 1, pp. 184-7, Jan. 2008.
2. M. Dawes, P. J. Chowienczyk. "Drugs in pregnancy. Pharmacokinetics in pregnancy," Best Pract Res Clin Obstet Gynaecol., vol 15, no. 6, pp. 819-26, Dec. 2001.
3. G.D.Anderson, "Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach," Clin Pharmacokinet., vol. 44, no. 10, pp. 989-1008, 2005..
4. C. D. Chambers, J. E. Polifka, J. M. Friedman, "Drug safety in pregnant women and their babies: ignorance not bliss," Clin Pharmacol Ther., vol. 83, no. 1, pp. 181-3, Jan. 2008.
5. R. A. Corley, T. J. Mast, E. W. Carney, J. M. Rogers, G. P. Daston, "Evaluation of physiologically based models of pregnancy and lactation for their application in children's health risk assessments," Crit Rev Toxicol., vol. 33, no. 2, pp. 137-211, 2003.
6. M. Kawahara, T. Nanbo, A. Tsuji, "Physiologically based pharmacokinetic prediction of p-phenylbenzoic acid disposition in the pregnant rat," Biopharm Drug Dispos., vol. 19, no. 7, pp. 445-53, Oct. 1998.
7. G. E. Blakey, I. A. Nestorov, P. A. Arundel, L. J. Aarons, M. Rowland, "Quantitative structure-pharmacokinetics relationships: I. Development of a whole-body physiologically based model to characterize changes in pharmacokinetics across a homologous series of barbiturates in the at," J Pharmacokinet Biopharm., vol. 25, no. 3, pp. 277-312, Jun. 1997.
8. R. P. Brown, M. D. Delp, S. L. Lindstedt, L. R. Rhomberg, R. P. Beliles, "Physiological parameter values for physiologically based pharmacokinetic models," Toxicol Ind Health, vol. 13, no. 4, pp. 407-84, Jul.-Aug. 1997.
9. S. Björkman, "Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs," Br J Clin Pharmacol., vol. 59, no. 6, pp. 691-704, Jun. 2005.
10. H. Allonen, G. Ziegler, and U. Klotz, "Midazolam kinetics," Clin Pharmacol Ther., vol. 30, no. 5, pp. 653-61, 1981.
11. J. Kanto, L. Aaltonen, R. Erkkola, L. Aärimaa, " Pharmacokinetics and sedative effect of midazolam in connection with caesarean section performed under epidural analgesia," Acta Anaesthesiol Scand., vol. 28, no. 1, pp. 116-8, Feb. 1984.
12. J. Kanto, S. Sjövall, R. Erkkola, J. J. Himberg, L. Kangas, "Placental transfer and maternal midazolam kinetics," Clin Pharmacol Ther., vol. 33, no. 6, pp. 786-91, Jun. 1983.
13. J. C. Gorski, D. R. Jones, B. D. Haehner-Daniels, M. A. Hamman, E. M. O'Mara, S. D. Hall, "The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin," Clin Pharmacol Ther., vol. 64, no. 2, pp. 133-43, Aug. 1998.
14. K. E. Thummel, D. O'Shea, M. F. Paine, D. D. Shen, K. L. Kunze, J. D. Perkins, G. R. Wilkinson. "Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism," Clin Pharmacol Ther., vol. 59, no. 5, pp. 491-502, May, 1996.